BioTuesdays

Category - Markets

Flex Pharma
Markets

Ladenburg ups Flex Pharma PT to $20 from $13

Ladenburg Thalmann raised its price target for Flex Pharma (NASDAQ:FLKS) to $20 from $13 after the company announced that its lead asset, FLX-787, reduced the frequency of cramps/spasms in a 57-patient, placebo...

March 29, 2018
Revance
Markets

Needham starts Revance Therapeutics at buy; PT $42

Needham initiated coverage of Revance Therapeutics (NASDAQ:RVNC) with a “buy” rating and $42 price target. The stock closed at $30.60 on March 26. Revance is involved in the development of novel and differentiated...

March 27, 2018
Profound Medical Logo
Markets

Paradigm ups Profound Medical PT to $3

Paradigm Capital raised its price target for Profound Medical (TSXV:PRN) to $3 from $2.25 after the company completed an upsized equity financing of $34.5-million. The stock closed at $1.05 on March 20. “We see this...

March 21, 2018
SELLAS Life Sciences Logo
Markets

Maxim ups Sellas Life Sciences to buy; PT $13

Maxim Group upgraded Sellas Life Sciences (NASDAQ:SLS) to “buy” from “hold,” with a $13 price target after meeting with Sellas management. The stock closed at $4.79 on March 16. Sellas completed a merger with Galena...

March 19, 2018
Markets

Piper upgrades Nuvectra to OW; PT to $16

Piper Jaffray upgraded Nuvectra (NASDAQ:NVTR) to “overweight” from “neutral” and raised its price target to $16 from $12 after the company reported fourth quarter results. The stock closed at $11.69 on March 15. The...

March 16, 2018
Volition
Markets

VolitionRx closes $8.4-million stock offering

VolitionRx (NYSE American:VNRX) closed an offering of 3.5 million common shares at a price of $2.40 a share for gross proceeds of $8.4-million. Volition, which develops blood tests to help diagnose a range of cancers...

March 14, 2018